|Report Code: PP10019||Report Type: Indication Pipeline Reports||Available format:|
Vitiligo is a type of autoimmune disorder which is characterized by white patches on skin. This is mainly due to destruction of melanocytes (cells responsible for pigmentation in the skin). People with certain autoimmune diseases are more prone to developing vitiligo. Some of the most common symptoms of the disease are occurrence of white patches on the hands, feet, arms, and lips. The disease can be managed by treatments such as laser therapy, phototherapy, micropigmentation, depigmentation therapy, and topical corticosteroids and calcineurin inhibitors.
Aclaris Therapeutics Inc. is actively developing ATI-50002 (Janus kinase (JAK) inhibitor), which is currently in the Phase II stage of development for the treatment of vitiligo. JN Bioscience LLC is in the process of developing ChMBC7 as an anti-CD122 antibody for the treatment of vitiligo. Some of the other companies developing vitiligo therapeutics are Dermavant Sciences Inc., 2A Pharma AB, and Incyte Corporation.